CLVR: AI 评分 47/100 — AI 分析 (4月 2026)

Clever Leaves Holdings Inc. is a global cannabis company operating through cannabinoid and non-cannabinoid segments. The company cultivates, extracts, manufactures, and distributes cannabinoid products internationally, while also offering nutraceutical and wellness products in the United States.

Key Facts: AI Score: 47/100 Sector: Healthcare

公司概况

概要：

Clever Leaves Holdings Inc., founded in 2017, operates in the global cannabis market, focusing on cannabinoid and non-cannabinoid products. With a presence in both international cannabinoid markets and the U.S. nutraceutical sector, the company faces challenges typical of the evolving cannabis industry, including regulatory hurdles and intense competition.

CLVR是做什么的？

Clever Leaves Holdings Inc., established in 2017, is a cannabis company headquartered in Boca Raton, Florida. The company operates through two primary segments: Cannabinoid and Non-Cannabinoid. The Cannabinoid segment is involved in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products on a global scale. This includes various cannabis-derived products targeted at medicinal and wellness applications. The Non-Cannabinoid segment focuses on the formulation, manufacturing, marketing, selling, and distribution of nutraceuticals, natural remedies, wellness products, detoxification products, and nutritional and dietary supplements. These products are primarily sold to mass retailers, specialty and health retailers, and distributors within the United States. Clever Leaves aims to leverage its international presence and diversified product portfolio to capture a significant share of the growing cannabis and wellness markets. However, the company faces challenges related to regulatory complexities, market competition, and achieving profitability.

CLVR的投资论点是什么？

Investing in Clever Leaves Holdings Inc. presents a high-risk, high-reward scenario. The company operates in the rapidly evolving cannabis industry, offering potential for significant growth but also exposing investors to substantial risks. Key value drivers include the expansion of its international cannabinoid operations and the growth of its nutraceutical business in the U.S. However, the company's negative profit margin of -102.8% and OTC market listing raise concerns about its financial stability and liquidity. Growth catalysts include potential regulatory changes in key markets and successful product launches. Investors should carefully consider the company's financial position, competitive landscape, and regulatory environment before investing. The high beta of 4.48 indicates significant volatility.

CLVR在哪个行业运营？

Clever Leaves operates within the rapidly expanding cannabis and nutraceutical industries. The global cannabis market is projected to reach billions of dollars in the coming years, driven by increasing legalization and acceptance of cannabis for medicinal and recreational purposes. The nutraceuticals market is also experiencing growth, fueled by rising consumer awareness of health and wellness. However, both industries are highly competitive and subject to evolving regulations. Clever Leaves competes with other cannabis producers and nutraceutical companies, facing challenges related to market access, product differentiation, and regulatory compliance.

Drug Manufacturers - Specialty & Generic

Healthcare

CLVR有哪些增长机遇？

Expansion of Cannabinoid Operations: Clever Leaves has the opportunity to expand its cannabinoid operations in international markets. As more countries legalize cannabis for medicinal or recreational use, the company can leverage its existing infrastructure and expertise to enter new markets and increase its market share. The global cannabis market is projected to reach $57 billion by 2027, offering significant growth potential for Clever Leaves.
Growth in the U.S. Nutraceutical Market: The company can capitalize on the growing demand for nutraceuticals and wellness products in the United States. By expanding its product portfolio and distribution network, Clever Leaves can increase its sales and market share in this segment. The U.S. nutraceutical market is estimated to be worth $80 billion, providing a substantial opportunity for Clever Leaves.
Strategic Partnerships and Acquisitions: Clever Leaves can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By partnering with other companies in the cannabis or nutraceutical industries, the company can gain access to new technologies, products, and markets. Acquisitions can also help Clever Leaves consolidate its position in key markets and increase its economies of scale.
Product Innovation and Differentiation: Clever Leaves can invest in research and development to create innovative and differentiated products that meet the evolving needs of consumers. By developing unique formulations and delivery methods, the company can gain a competitive advantage and increase its brand recognition. This includes exploring new cannabinoid-based therapies and novel nutraceutical products.
Regulatory Changes and Market Liberalization: Changes in regulations and market liberalization can create new opportunities for Clever Leaves. As more countries and states legalize cannabis, the company can expand its operations and access new markets. Monitoring and adapting to regulatory changes will be crucial for Clever Leaves to capitalize on these opportunities. This includes advocating for favorable regulations and participating in industry discussions.

Clever Leaves operates in the Cannabinoid segment, focusing on cultivation, extraction, and distribution of cannabis products internationally.
The company's Non-Cannabinoid segment formulates and sells nutraceuticals and wellness products in the United States.
Clever Leaves was founded in 2017 and is based in Boca Raton, Florida.
The company has a gross margin of 37.6%.
Clever Leaves has 296 employees.

CLVR提供哪些产品和服务？

Cultivates cannabis plants for cannabinoid extraction.
Extracts cannabinoids from cannabis plants.
Manufactures cannabinoid-based products.
Commercializes and distributes cannabinoid products internationally.
Formulates nutraceutical and wellness products.
Markets and sells nutraceutical products in the United States.
Distributes nutraceuticals to mass retailers, specialty stores, and distributors.

CLVR如何赚钱？

Cultivation and extraction of cannabinoids for sale to manufacturers and distributors.
Manufacturing and sale of cannabinoid-based products to consumers and businesses.
Formulation, manufacturing, and sale of nutraceutical and wellness products in the U.S.
Distribution through mass retailers, specialty stores, and distributors.

Cannabis product manufacturers and distributors.
Consumers seeking cannabinoid-based products.
Mass retailers in the United States.
Specialty and health retailers in the United States.

International presence in the cannabinoid market.
Diversified product portfolio across cannabinoid and non-cannabinoid segments.
Established distribution network in the United States.
Expertise in cannabis cultivation and extraction.

什么因素可能推动CLVR股价上涨？

Upcoming: Potential regulatory changes in key international markets could open new opportunities for cannabinoid product sales.
Upcoming: Successful product launches in the U.S. nutraceutical market could drive revenue growth.
Ongoing: Expansion of the company's distribution network in the United States.
Ongoing: Strategic partnerships and acquisitions to expand market reach.
Ongoing: Research and development efforts to create innovative and differentiated products.

CLVR的主要风险是什么？

Ongoing: Evolving and uncertain regulatory landscape in the cannabis industry.
Ongoing: Intense competition in both the cannabis and nutraceutical markets.
Potential: Fluctuations in commodity prices could impact profitability.
Potential: Product recalls or liability claims could damage the company's reputation and financial performance.
Potential: Limited access to capital due to OTC market listing.

CLVR的核心优势是什么？

Diversified product portfolio (cannabinoid and non-cannabinoid).
International presence in key cannabis markets.
Established distribution network in the U.S. nutraceutical market.
Expertise in cannabis cultivation and extraction.

CLVR的劣势是什么？

Negative profit margin.
High beta indicating significant volatility.
OTC market listing raises liquidity concerns.
Dependence on regulatory changes in the cannabis industry.

CLVR有哪些机遇？

Expansion into new international cannabis markets.
Growth in the U.S. nutraceutical market.
Strategic partnerships and acquisitions.
Product innovation and differentiation.

CLVR面临哪些威胁？

Evolving and uncertain regulatory landscape.
Intense competition in the cannabis and nutraceutical industries.
Fluctuations in commodity prices.
Potential for product recalls or liability claims.

CLVR的竞争对手是谁？

BioCryst Pharmaceuticals, Inc. — Focuses on rare disease therapeutics. — (BIOCQ)
Brain Scientific Inc. — Develops neurological diagnostic devices. — (BRSF)
Biopharmx Corp. — Specializes in dermatology products. — (BSPM)
Craftport Cannabis Corp. — Operates in the cannabis industry. — (CRFTF)
Encode Ideas, Inc. — Provides investment research and consulting. — (ENCW)

Key Metrics

MoonshotScore: 47/100

Company Profile

CEO: Andres Fajardo
Headquarters: Boca Raton, US
Employees: 296
Founded: 2020

AI Insight

AI analysis pending for CLVR

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Clever Leaves Holdings Inc. do?

Clever Leaves Holdings Inc. operates as a global cannabis company with two segments: Cannabinoid and Non-Cannabinoid. The Cannabinoid segment focuses on the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment formulates, manufactures, markets, sells, and distributes nutraceutical and wellness products in the United States. The company aims to leverage its international presence and diversified product portfolio to capture a significant share of the growing cannabis and wellness markets.

What do analysts say about CLVR stock?

AI analysis for CLVR is currently pending. Without analyst consensus or ratings, investors should conduct thorough independent research, considering the company's financial performance, market position, and risk factors. Key valuation metrics to monitor include revenue growth, gross margin, and profitability. Growth considerations include the expansion of its international cannabinoid operations and the growth of its nutraceutical business in the U.S. Investors should also carefully consider the company's OTC market listing and associated risks.

What are the main risks for CLVR?

Clever Leaves faces several key risks, including the evolving and uncertain regulatory landscape in the cannabis industry, intense competition in both the cannabis and nutraceutical markets, fluctuations in commodity prices, and the potential for product recalls or liability claims. The company's OTC market listing also raises concerns about liquidity and access to capital. Investors should carefully consider these risks before investing in Clever Leaves.

How does Clever Leaves Holdings Inc. navigate regulatory approval processes?

As a cannabis company, Clever Leaves Holdings Inc. faces complex regulatory approval processes in various jurisdictions. The company must comply with regulations related to cultivation, extraction, manufacturing, and distribution of cannabis products. Specific details regarding Clever Leaves' FDA/EMA regulatory track record, pending approvals, and compliance strategy are not available in the provided data. However, the company's ability to navigate these regulatory hurdles will be crucial for its long-term success.

How does Clever Leaves Holdings Inc. manage its supply chain for cannabis production?

Managing the supply chain is critical for Clever Leaves to ensure consistent product quality and availability. This includes sourcing raw materials, managing cultivation and extraction processes, and ensuring efficient distribution. Specific details about Clever Leaves' supply chain management practices are not available in the provided data. However, the company's ability to effectively manage its supply chain will be essential for maintaining its competitive advantage and meeting customer demand.